VIRAX BIOLABS GROUP LTD (VRAX) Stock Fundamental Analysis

NASDAQ:VRAX • KYG9495L1251

0.213 USD
-0.01 (-5.33%)
At close: Feb 20, 2026
0.22 USD
+0.01 (+3.29%)
After Hours: 2/20/2026, 8:09:46 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to VRAX. VRAX was compared to 101 industry peers in the Health Care Providers & Services industry. While VRAX seems to be doing ok healthwise, there are quite some concerns on its profitability. VRAX is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year VRAX has reported negative net income.
  • In the past year VRAX has reported a negative cash flow from operations.
  • VRAX had negative earnings in each of the past 5 years.
  • VRAX had a negative operating cash flow in each of the past 5 years.
VRAX Yearly Net Income VS EBIT VS OCF VS FCFVRAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -2M -4M -6M

1.2 Ratios

  • VRAX has a worse Return On Assets (-98.75%) than 93.07% of its industry peers.
  • VRAX has a worse Return On Equity (-106.24%) than 77.23% of its industry peers.
Industry RankSector Rank
ROA -98.75%
ROE -106.24%
ROIC N/A
ROA(3y)-90.9%
ROA(5y)-1063.54%
ROE(3y)-97.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VRAX Yearly ROA, ROE, ROICVRAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for VRAX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRAX Yearly Profit, Operating, Gross MarginsVRAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 -20K -40K -60K -80K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • VRAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for VRAX has been increased compared to 1 year ago.
  • The number of shares outstanding for VRAX has been reduced compared to 5 years ago.
  • VRAX has a worse debt/assets ratio than last year.
VRAX Yearly Shares OutstandingVRAX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
VRAX Yearly Total Debt VS Total AssetsVRAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

2.2 Solvency

  • VRAX has an Altman-Z score of 1.07. This is a bad value and indicates that VRAX is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.07, VRAX is doing worse than 67.33% of the companies in the same industry.
  • VRAX has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
  • VRAX has a Debt to Equity ratio of 0.09. This is in the better half of the industry: VRAX outperforms 75.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 1.07
ROIC/WACCN/A
WACC11.16%
VRAX Yearly LT Debt VS Equity VS FCFVRAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 5M -5M

2.3 Liquidity

  • VRAX has a Current Ratio of 11.35. This indicates that VRAX is financially healthy and has no problem in meeting its short term obligations.
  • VRAX's Current ratio of 11.35 is amongst the best of the industry. VRAX outperforms 98.02% of its industry peers.
  • A Quick Ratio of 11.20 indicates that VRAX has no problem at all paying its short term obligations.
  • The Quick ratio of VRAX (11.20) is better than 98.02% of its industry peers.
Industry RankSector Rank
Current Ratio 11.35
Quick Ratio 11.2
VRAX Yearly Current Assets VS Current LiabilitesVRAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • VRAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.89%, which is quite impressive.
  • Looking at the last year, VRAX shows a very negative growth in Revenue. The Revenue has decreased by -96.47% in the last year.
  • Measured over the past years, VRAX shows a very negative growth in Revenue. The Revenue has been decreasing by -42.47% on average per year.
EPS 1Y (TTM)51.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.72%
Revenue 1Y (TTM)-96.47%
Revenue growth 3YN/A
Revenue growth 5Y-42.47%
Sales Q2Q%-68%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • VRAX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.04% yearly.
EPS Next Y166.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year66.97%
Revenue Next 2Y-29.64%
Revenue Next 3Y-4.67%
Revenue Next 5Y16.04%

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VRAX Yearly Revenue VS EstimatesVRAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5M 10M 15M 20M 25M
VRAX Yearly EPS VS EstimatesVRAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 0 -0.05 -0.1 -0.15

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • VRAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 5.22 indicates a rather cheap valuation of VRAX.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of VRAX indicates a rather cheap valuation: VRAX is cheaper than 97.03% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.02, VRAX is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 5.22
VRAX Price Earnings VS Forward Price EarningsVRAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRAX Per share dataVRAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

  • VRAX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • VRAX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VIRAX BIOLABS GROUP LTD

NASDAQ:VRAX (2/20/2026, 8:09:46 PM)

After market: 0.22 +0.01 (+3.29%)

0.213

-0.01 (-5.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A
Earnings (Next)12-13
Inst Owners6.97%
Inst Owner ChangeN/A
Ins Owners5.64%
Ins Owner ChangeN/A
Market Cap1.58M
Revenue(TTM)3.00K
Net Income(TTM)-5.64M
Analysts82.86
Price Target1.02 (378.87%)
Short Float %0.92%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-95%
PT rev (3m)-95%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.22
P/S 526.82
P/FCF N/A
P/OCF N/A
P/B 0.3
P/tB 0.3
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)0.04
Fwd EY19.15%
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.73
OCFYN/A
SpS0
BVpS0.72
TBVpS0.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -98.75%
ROE -106.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.9%
ROA(5y)-1063.54%
ROE(3y)-97.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 123.76%
Cap/Sales 16580%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.35
Quick Ratio 11.2
Altman-Z 1.07
F-Score1
WACC11.16%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)4134.9%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.72%
EPS Next Y166.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-96.47%
Revenue growth 3YN/A
Revenue growth 5Y-42.47%
Sales Q2Q%-68%
Revenue Next Year66.97%
Revenue Next 2Y-29.64%
Revenue Next 3Y-4.67%
Revenue Next 5Y16.04%
EBIT growth 1Y6.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year161.03%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.95%
OCF growth 3YN/A
OCF growth 5YN/A

VIRAX BIOLABS GROUP LTD / VRAX FAQ

Can you provide the ChartMill fundamental rating for VIRAX BIOLABS GROUP LTD?

ChartMill assigns a fundamental rating of 3 / 10 to VRAX.


What is the valuation status for VRAX stock?

ChartMill assigns a valuation rating of 4 / 10 to VIRAX BIOLABS GROUP LTD (VRAX). This can be considered as Fairly Valued.


Can you provide the profitability details for VIRAX BIOLABS GROUP LTD?

VIRAX BIOLABS GROUP LTD (VRAX) has a profitability rating of 0 / 10.